Incidence and Prevalence of Acromegaly in the United States: A Claims-Based Analysis |
| |
| Affiliation: | 1. From the Partnership for Health Analytic Research, LLC, Beverly Hills, California;2. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;3. Chiasma, Inc, Waltham, Massachusetts (previously of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey).;1. Department of Medicine, Division of Endocrinology and Center for Endocrine Tumors Leiden (CETL), Leiden University Medical Center, Leiden, The Netherlands;2. Department of Medical Psychology, Leiden University Medical Center, Leiden, The Netherlands;3. Psychological Science, University of California, Merced, CA, United States;1. From the Department of Neurosurgery, University of Duisburg-Essen, Hufelandstr, Essen, Germany;2. Department of Neurosurgery, Friedrich-Alexander University (FAU) of Erlangen-Nuremberg, Schwabachanlage, Erlangen, Germany;3. Institute of Neuropathology, Friedrich-Alexander University (FAU) of Erlangen-Nuremberg, Schwabachanlage, Erlangen, Germany;4. Department of Women''s and Children''s Health, Uppsala University, Akademiska Sjukhuset, Uppsala, Sweden;5. Department of Endocrinology, Diabetes and Nutritional Medicine, Campus Charité Mitte, Charité Universitaetsmedizin, Berlin, Germany;2. Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands;3. Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Erasmus MC Medical University Center Rotterdam, Rotterdam, The Netherlands;4. Department of Otolaryngology/Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands;5. Department of Rehabilitation, Section of Speech and Language Therapy, Radboud University Medical Center, Nijmegen, The Netherlands |
| |
| Abstract: | Objective: Acromegaly, a rare endocrine disorder, results from excessive growth hormone secretion, leading to multisystem-associated morbidities. Using 2 large nationwide databases, we estimated the annual incidence and prevalence of acromegaly in the U.S.Methods: We used 2008 to 2013 data from the Truven Health MarketScan® Commercial Claims and Encounters Database and IMS Health PharMetrics healthcare insurance claims databases, with health plan enrollees <65 years of age. Study patients had ≥2 claims with acromegaly (International Classification of Diseases, 9th Revision, Clinical Modification Code [ICD-9CM] 253.0), or 1 claim with acromegaly and 1 claim for pituitary tumor, pituitary surgery, or cranial stereotactic radiosurgery. Annual incidence was calculated for each year from 2009 to 2013, and prevalence in 2013. Estimates were stratified by age and sex.Results: Incidence was up to 11.7 cases per million person-years (PMPY) in MarketScan and 9.6 cases PMPY in PharMetrics. Rates were similar by sex but typically lowest in ≤17 year olds and higher in >24 year olds. The prevalence estimates were 87.8 and 71.0 per million per year in MarketScan and PharMetrics, respectively. Prevalence consistently increased with age but was similar by sex in each database.Conclusion: The current U.S. incidence of acromegaly may be up to 4 times higher and prevalence may be up to 50% higher than previously reported in European studies. Our findings correspond with the estimates reported by a recent U.S. study that used a single managed care database, supporting the robustness of these estimates in this population. Our study indicates there are approximately 3,000 new cases of acromegaly per year, with a prevalence of about 25,000 acromegaly patients in the U.S.Abbreviations:CT = computed tomographyGH = growth hormoneIGF-1 = insulin-like growth factor 1ICD-9-CM Code = International Classification of Diseases, 9th Revision, Clinical Modification CodesMRI = magnetic resonance imagingPMPY = per million person-years |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
